FULC241018P3000
- 0.15
- 0.000.00%
Fulcrum Therapeutics Newsroom
Fulcrum Therapeutics Shares Rise 26% on Sickle Cell Disease Market Opportunity
12 Health Care Stocks Moving In Thursday's Intraday Session
Fulcrum Therapeutics Potential Winner After Pfizer Pulls Oxbryta -- Market Talk
Express News | Fulcrum Therapeutics Shares up 31% After Rival Pfizer Withdraws Sickle Cell Disease Treatment
Fulcrum Therapeutics to Cut Jobs, Reprioritize R&D Activities
Fulcrum Reduces Its Workforce
Express News | Fulcrum Therapeutics Inc: Board Approved Plan to Reprioritize Research and Development Activities
Express News | Fulcrum Therapeutics Inc: Expects Majority of Costs Associated With Reduction to Be Incurred During Q3 Ending September 30, 2024
Express News | Fulcrum Therapeutics Inc: Plan to Reduce Co's Workforce From 80 to 51 Full-Time Employees
Domain Timber Advisors Selected by Fulcrum Asset Management to Drive Sustainable Investments in U.S. Forestland
Express News | Tcg Crossover Gp II, LLC Reports 9.4% Passive Stake in Fulcrum Therapeutics as of Sept 12 - SEC Filing
Solicitation for Bids of the Assets of Fulcrum Sierra BioFuels, LLC and Fulcrum BioEnergy, Inc.
RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics Shares Are Trading Lower After HC Wainwright & Co and RBC Capital Downgraded the Company and Lowered Their Respective Price Targets on the Stock.
FULC Stock Falls as Muscle Disorder Study Misses Primary Goal
Breaking Down Fulcrum Therapeutics: 7 Analysts Share Their Views
A Quick Look at Today's Ratings for Fulcrum Therapeutics(FULC.US), With a Forecast Between $2 to $22
Express News | Fulcrum Therapeutics Shares Down 3% Premarket After 61% Drop in Previous Session
Hold Rating on Fulcrum Therapeutics Amid Phase 3 Drug Failure and Pivot to Sickle Cell Disease Candidate